TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:11
Nuvectis Pharma Inc. ( NVCT ) https://www.nuvectis.com
8.26USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-31.17%
NVCT
SPY
32.74%
NVCT
0.00%
SPY
92.93%
NVCT
0.00%
SPY
224.41%
NVCT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
157.64
138.51
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-7.13
1057.99
12.92
0.00
0.00
-6.29
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-2752.35
2752.35
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-184.90
-186.46
0.00
Other Earnings and Cash Flow Stats:
Nuvectis Pharma Inc. ( NVCT ) Net Income TTM ($MM) is -22.16
Nuvectis Pharma Inc. ( NVCT ) Operating Income TTM ($MM) is -22.97
Nuvectis Pharma Inc. ( NVCT ) Owners' Earnings Annual ($MM) is 0.00
Nuvectis Pharma Inc. ( NVCT ) Current Price to Owners' Earnings ratio is 0.00
Nuvectis Pharma Inc. ( NVCT ) EBITDA TTM ($MM) is -22.53
Nuvectis Pharma Inc. ( NVCT ) EBITDA Margin is 0.00%
Capital Allocation:
Nuvectis Pharma Inc. ( NVCT ) has paid 0.00 dividends per share and bought back -4.761235 million shares in the past 12 months
Nuvectis Pharma Inc. ( NVCT ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Nuvectis Pharma Inc. ( NVCT ) Interest-bearing Debt ($MM) as of last quarter is 0
Nuvectis Pharma Inc. ( NVCT ) Annual Working Capital Investments ($MM) are -2
Nuvectis Pharma Inc. ( NVCT ) Book Value ($MM) as of last quarter is 12
Nuvectis Pharma Inc. ( NVCT ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Nuvectis Pharma Inc. ( NVCT ) has 19 million in cash on hand as of last quarter
Nuvectis Pharma Inc. ( NVCT ) has 6 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Nuvectis Pharma Inc. ( NVCT ) has 17 common shares outstanding as of last quarter
Nuvectis Pharma Inc. ( NVCT ) has 0 million USD of preferred stock value
Academic Scores:
Nuvectis Pharma Inc. ( NVCT ) Altman Z-Score is 6.53 as of last quarter
Nuvectis Pharma Inc. ( NVCT ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Nuvectis Pharma Inc. ( NVCT ) largest shareholder is Tower Research Capital LLC owning 7282 shares at 0.06 ($MM) value
BENTSUR RON(an insider) Bought 5000 shares of Nuvectis Pharma Inc. ( NVCT ) for the amount of $51450.00 on 2024-03-18
55.86% of Nuvectis Pharma Inc. ( NVCT ) is held by insiders, and 18.67% is held by institutions
Nuvectis Pharma Inc. ( NVCT ) went public on 2022-02-04
Other Nuvectis Pharma Inc. ( NVCT ) financial metrics:
FCF:-15.96
Unlevered Free Cash Flow:0.00
EPS:-1.35
Operating Margin:-2752.35
Gross Profit Margin:2752.35
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-192.80
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Nuvectis Pharma Inc. ( NVCT ) :
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.